Expanding the availability of clinical trial data, particularly negative results, may not necessarily be a key to promoting more drug repurposing.
Releasing more data may further cloud the arena, a GlaxoSmithKline PLC executive said, and the process would not necessarily...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?